WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1)]. Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC.
ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1)]. WARNING: CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning.
Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. (5.1) Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
(1)
Use: Labeled indications
- ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
(1) Limitations of Use: ULORIC is not recommended for the treatment of asymptomatic hyperuricemia. (1) Limitations of Use: ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.
Contraindications
- Concomitant azathioprine or mercaptopurine
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7)]. ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine. (4)
Dosing: Adult
- Chronic hyperuricemia in gout (allopurinol inadequate, not tolerated or inadvisable): Start 40 mg once daily; 80 mg once daily if serum urate is not below 6 mg/dL after 2 weeks; limit to 40 mg in severe kidney impairment
- Recommended dosage is 40 mg or 80 mg once daily. The recommended starting dosage is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after 2 weeks, the recommended dosage is 80 mg once daily. (2.1)
- Patients with severe renal impairment: Limit the dosage to 40 mg once daily. (2.2, 8.6)
- Flare prophylaxis is recommended upon initiation of ULORIC. (2.4)
- Can be administered without regard to food or antacid use. (2.1)
2.1 Recommended Dosage
2.1 Recommended Dosage The recommended ULORIC dosage is 40 mg or 80 mg once daily. The recommended starting dosage of ULORIC is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after two weeks, the recommended ULORIC dosage is 80 mg once daily. ULORIC can be taken without regard to food or antacid use [see Clinical Pharmacology (12.3)].
Concurrent prophylactic treatment with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].
2.2 Dosage Recommendations in Patients with Renal Impairment and Hepatic
2.2 Dosage Recommendations in Patients with Renal Impairment and Hepatic Impairment The recommended dosage of ULORIC is limited to 40 mg once daily in patients with severe renal impairment. No dose modification is necessary when administering ULORIC in patients with mild or moderate renal impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
No dosage modification is necessary in patients with mild to moderate hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
2.3 Serum Uric Acid Level Monitoring
2.3 Serum Uric Acid Level Monitoring Testing for the target serum uric acid level of less than 6 mg/dL may be performed as early as two weeks after initiating ULORIC therapy.
2.4 Recommended Prophylaxis for Gout Flares
2.4 Recommended Prophylaxis for Gout Flares Gout flares may occur after initiation of ULORIC due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. Flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended upon initiation of ULORIC. Prophylactic therapy may be beneficial for up to six months [see Clinical Studies (14.1)].
If a gout flare occurs during ULORIC treatment, ULORIC need not be discontinued. The gout flare should be managed concurrently, as appropriate for the individual patient [see Warnings and Precautions (5.2)].
Dosing: Altered kidney function
Febuxostat needs no dose change in mild to moderate kidney impairment. In severe impairment the US label limits the dose to 40 mg once daily, and it has not been studied in people on dialysis.
Kidney function measure: Label uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- No dose adjustment (label: mild impairment, CrCl 30 to 89 mL/min, needs none).
- CrCl 30–59 mL/min
- No dose adjustment (label: moderate impairment).
- CrCl 15–29 mL/min
- Limit to 40 mg once daily (label).
- CrCl <15 mL/min (not on dialysis)
- Not studied (PK study enrolled CrCl 10 to 29 mL/min). Insufficient data: use with specialist input.
- Hemodialysis (intermittent)
- Not studied in end-stage renal impairment on dialysis (label). Insufficient data: use with specialist input.
- Peritoneal dialysis
- Not studied (label). Insufficient data: use with specialist input.
- CRRT
- No data in label. Insufficient data: use with specialist input.
- Dialyzable? Unknown: not studied (label).
- Monitoring Serum urate; liver tests per label. The label carries a boxed warning on cardiovascular death.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Not established in children; do not use outside specialist care.
- eGFR 30–59
- Not established in children; do not use outside specialist care.
- eGFR 15–29
- Not established in children; do not use outside specialist care.
- eGFR <15 (not on dialysis)
- Not established in children; do not use outside specialist care.
- Hemodialysis (intermittent)
- Not established.
- Peritoneal dialysis
- Not established.
- CRRT
- Not established.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.2 Dosage Recommendations in Patients with Renal Impairment and Hepatic Impairment The recommended dosage of ULORIC is limited to 40 mg once daily in patients with severe renal impairment. No dose modification is necessary when administering ULORIC in patients with mild or moderate renal impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. No dosage modification is necessary in patients with mild to moderate hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
8.6 Renal Impairment No dose adjustment is necessary in patients with mild to moderate renal impairment (Cl cr 30 to 89 mL/min). For patients with severe renal impairment (Cl cr 15 to 29 mL/min), the recommended dosage of ULORIC is limited to 40 mg once daily [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].
Patients with Renal Impairment In a dedicated phase I pharmacokinetics study, following multiple 80 mg doses of ULORIC in healthy patients with mild (Cl cr 50 to 80 mL/min), moderate (Cl cr 30 to 49 mL/min) or severe renal impairment (Cl cr 10 to 29 mL/min), the C max of febuxostat did not change relative to patients with normal renal function (Cl cr greater than 80 mL/min). AUC and half-life of febuxostat increased in patients with renal impairment in comparison to patients with normal renal function, but values were similar among three renal impairment groups.
Mean febuxostat AUC values were up to 1.8 times higher in patients with renal impairment compared to those with normal renal function. Mean C max and AUC values for three active metabolites increased up to two and four-fold, respectively. However, the percent decrease in serum uric acid concentration for patients with renal impairment was comparable to those with normal renal function (58% in normal renal function group and 55% in the severe renal function group).
Based on population pharmacokinetic analysis, following multiple 40 mg or 80 mg doses of ULORIC, the mean oral clearance (CL/F) values of febuxostat in patients with gout and mild (n=334), moderate (n=232) or severe (n=34) renal impairment were decreased by 14%, 34%, and 48%, respectively, compared to patients with normal (n=89) renal function. The corresponding median AUC values of febuxostat at steady-state in patients with renal impairment were increased by 18%, 49%, and 96% after 40 mg dose, and 7%, 45% and 98% after 80 mg dose, respectively, compared to patients with normal renal function.
ULORIC has not been studied in end stage renal impairment patients who are on dialysis.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C); therefore, caution should be exercised in these patients [see Clinical Pharmacology (12.3)].
2.2 Dosage Recommendations in Patients with Renal Impairment and Hepatic Impairment The recommended dosage of ULORIC is limited to 40 mg once daily in patients with severe renal impairment. No dose modification is necessary when administering ULORIC in patients with mild or moderate renal impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. No dosage modification is necessary in patients with mild to moderate hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
- Approved ages
- Safety and effectiveness not established in pediatric patients (label).
- Usual dose
- Not established; no pediatric dose.
- Maximum dose
- Not applicable.
- Neonates
- Neonates: specialist input (not established).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of ULORIC in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No dose adjustment is necessary in elderly patients. Of the total number of patients in Studies 1, 2, and 3 (clinical studies of ULORIC in the treatment of gout) [see Clinical Studies (14.1)], 16% were 65 and over, while 4% were 75 and over. Comparing patients in different age groups, no clinically significant differences in safety or effectiveness were observed but greater sensitivity of some older individuals cannot be ruled out.
The C max and AUC 24 of febuxostat following multiple oral doses of ULORIC in geriatric patients (≥65 years) were similar to those in younger patients (18 to 40 years) [see Clinical Pharmacology (12.3)].
Dosage forms
Philippines
- Film-coated tablet: 20 mg, 40 mg, 80 mg, 120 mg
- Tablet: 40 mg, 80 mg
Registered products in the Philippines
218 products registered with the Food and Drug Administration (FDA) Philippines list Febuxostat as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products218
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AfebxFebuxostat | 40 mg Film Coated Tablet3 x 10 Tablet Alu-Alu Blister Pack | Rx | AMN Life Pvt. Ltd.India | ASA Life Philippines Limited Inc. | DRP-19037 | Oct 19, 2031 | |
Afebx 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x10's (Box of 30's) | Rx | AMN Life Pvt. Ltd.India | ASA Life Philippines Limited Inc. | DRP-18935 | Oct 5, 2031 | |
Afixostat 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-12601 | Sep 14, 2027 | |
Afixostat 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-12600 | Sep 14, 2027 | |
Altoxustat 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-10512-08 | Sep 22, 2037 | |
Amburix 40Febuxostat | 40 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Hebei Tiancheng Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-17089 | Sep 24, 2030 | |
Amburix 80Febuxostat | 80 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Hebei Tiancheng Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-17088 | Sep 24, 2030 | |
Amfebb-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 10's, 30's, and 100's) | Rx | Innova Captab Ltd. (Unit II)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14532-04 | Oct 3, 2028 | |
Amfebb-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 100's) | Rx | Innova Captab LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14531-03 | Oct 3, 2028 | |
AtenugenFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Alternative Platform Exchange, Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-06 | Sep 14, 2027 | |
AtenugenFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 10, 30's, and 100's) | Rx | Innova Captab LimitedIndia | Alternative Platform Exchange, Inc.Importer: Ambica International Corporation | DRP-14532-03 | Oct 3, 2028 | |
AtenurixFebuxostat | 120mg Film-Coated TabletAlu/Alu Blister Pack X 10'S (Box Of 30'S) | Rx | Ajanta Pharma Ltd.India | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY38998 | Apr 4, 2027 | |
AtenurixFebuxostat | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DR-XY48065 | Feb 20, 2031 | |
AtenurixFebuxostat | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DR-XY43526 | Jul 8, 2029 | |
AtenurixFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma Ltd.India | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY38996 | Mar 7, 2027 | |
AtenurixFebuxostat | 80mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma Ltd.India | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY38997 | Mar 7, 2027 | |
Bristat 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Britton Distributions, Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-07 | Sep 14, 2027 | |
BufecorFebuxostat | 80 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Uni MedicolabsIndia | Greencore Pharma Inc. | DRP-18968 | Oct 8, 2031 | |
EA FexustanFebuxostat | 80 mg Film Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc. | DRP-13234 | Jan 6, 2028 | |
EfuboricFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-10512-01 | Aug 26, 2037 | |
Efuboric DSFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-10511-04 | Aug 12, 2037 | |
EmdirixFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | MD9 Pharma And Distribution Inc.Importer: Bliss Pharma Distribution And Consultancy Corp. | DRP-12601-05 | Sep 14, 2027 | |
EuricstatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | The Acme Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DR-XY49076 | May 10, 2029 | |
FabsFebuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Gracure Pharmaceuticals LimitedIndia | Stangen Pharmaceuticals Philippines Inc. | DRP-10426 | Nov 4, 2031 | |
Febdiaff-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 100's) | Rx | Innova Captab LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-14532-02 | Oct 3, 2028 | |
Febdiaff-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | Rx | Innova Captab Ltd. (Unit II)India | Diafarm Inc.Importer: Ambica International Corporation | DRP-14531-01 | Oct 3, 2028 | |
Feblorika 80Febuxostat | 80mg Film-Coated TabletAlu/Alu blister pack x10's (Box of 30's) | Rx | Mankind Pharma Limited (Unit II)India | Macropharma Corporation | DRP-13084 | Nov 25, 2027 | |
Feblorika-40Febuxostat | 40mg TabletsAlu/Alu blister pack x10's (Box of 30's) | Rx | Mankind Pharma Limited (Unit II)India | Macropharma Corporation | DRP-13411 | Feb 16, 2028 | |
Febox-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Triple 888 Medical and Pharma Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-03 | Apr 4, 2027 | |
FeboxstabFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-10511-05 | Aug 6, 2037 | |
Febsan 120Febuxostat | 120 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 10's | Rx | ACME Formulation Pvt. Ltd.India | IMV Gemini Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-13226 | Oct 29, 2029 | |
Febsan 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | ACME Formulation Pvt. Ltd.India | IMV Gemini Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-13228 | Oct 29, 2029 | |
Febsan 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | ACME Formulation Pvt. Ltd.India | IMV Gemini Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-13227 | Oct 29, 2029 | |
Febstat 40Febuxostat | 40 mg Film-Coated TabletAlu/ Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Airlife International Trading CorporationImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-12 | Sep 14, 2027 | |
Febstat 40Febuxostat | 40 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | AIRLIFE INTERNATIONAL TRADING CORPORATIONImporter: RV GROUP PHIL. BRANCH | DRP-13982-02 | May 31, 2028 | |
Febstat 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Airlife International Trading CorporationImporter: Bliss Pharma Distribution And Consultancy Corp. | DRP-12600-09 | Sep 14, 2027 | |
Febstat 80Febuxostat | 80 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | Airlife International Trading CorporationImporter: RV Group Phil. Branch | DRP-13981-01 | May 31, 2028 | |
Febtout 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Adnova Healthcare Pvt. Ltd.India | SRS Life Sciences Inc. | DR-XY49080 | May 15, 2029 | |
FebuCassFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Acme Formulation Pvt. Ltd.India | Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc. | DRP-11461-01 | Mar 15, 2027 | |
FebuctFebuxostat | 40 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Genuone Sciences Inc.Korea | JLT Pharma Inc.. | DRP-16369 | Feb 20, 2030 | |
FebuctFebuxostat | 80 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Genuone Sciences Inc.Korea | JLT Pharma Inc. | DRP-16368 | Feb 20, 2030 | |
Febuday 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | MSN LABORATORIES PRIVATE LIMITED (FORMULATION DIVISION)India | HEALOL PHARMA CORPORATION | DRP-8533 | Jul 20, 2027 | |
Febufast 120Febuxostat | 120 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | MSN Laboratories Private Limited (Formulations Division)India | Preventia Healthcare Inc. | DRP-13619 | Mar 17, 2028 | |
Febufast 40Febuxostat | 40 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | Rx | ACME Formulation Pvt. Ltd.India | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-11052-01 | Jan 19, 2032 | |
Febufast 40Febuxostat | 40 mg Film-Coated TabletWhite opaque HDPE Bottle and white opaque Polypropylene child-resistant closure with induction seal x 30's (in a Box) | Rx | MSN Laboratories Private Limited (Formulations Division)India | Preventia Healthcare Inc. | DRP-16395 | Mar 4, 2030 | |
Febufast 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-10613-01 | Feb 6, 2032 | |
Febufast 80Febuxostat | 80 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | MSN Laboratories Private Limited (Formulations Division)India | Preventia Healthcare Inc. | DRP-16394 | Mar 4, 2030 | |
Febufree 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-03 | Sep 14, 2027 | |
Febufree 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-03 | Sep 14, 2027 | |
FebugenFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Flourish PharmaIndia | Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-17450 | Dec 18, 2030 | |
FebuhilFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-01 | Apr 4, 2027 | |
Febulas 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DR-XY49027 | Mar 26, 2029 | |
Febulas 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DR-XY49017 | Mar 26, 2029 | |
FebulittFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Littman Drug CorporationImporter: Ambica International Corporation | DRP-12292-05 | Jul 12, 2027 | |
Febuliv 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | RV Group Phil. Branch | DRP-13982 | May 31, 2028 | |
Febuliv 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | RV Group Phil. Branch | DRP-13981 | May 31, 2028 | |
Febultra 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Ultramed Pharma, Inc.Importer: Ambica International Corporation | DRP-12292-08 | Jul 12, 2032 | |
FebumaxFebuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Sanimed Pharmaceuticals Inc. | DRP-11620 | Apr 4, 2027 | |
Febumed-80Febuxostat | 80mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Acme Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-11461 | Mar 15, 2027 | |
FebunazFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab LimitedIndia | All-Bio Pharma, Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10408 | Aug 1, 2029 | |
FebunazFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab Ltd.India | All-Bio Pharma, Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10409 | Aug 1, 2029 | |
Febunol-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10512 | Oct 7, 2030 | |
Febunol-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-10511 | Oct 7, 2031 | |
FebunormFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Innova Captab LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14532-06 | Oct 3, 2028 | |
FebunormFebuxostat | 80 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | Rx | Innova Captab Ltd. (Unit II)India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14531-04 | Oct 3, 2028 | |
FebuphilFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma, Inc.Importer: Ambica International Corporation | DRP-10512-04 | Aug 28, 2037 | |
FebuPrime 40Febuxostat | 40 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | Primecare Pharmaceutical DistributorsImporter: RV Group Phil. Branch | DRP-13982-01 | May 31, 2028 | |
FebuPrime 80Febuxostat | 80 mg Film-Coated TabletAlu / Alu blister pack x 10's (Box of 30's) | Rx | RV Lifesciences LimitedIndia | Primecare Pharmaceutical DistributorsImporter: RV Group Phil. Branch | DRP-13981-02 | May 31, 2028 | |
FebuproFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-06 | Apr 4, 2027 | |
Febured 40Febuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack of 10’s (Box of 10’s, 30's and 100's) | Rx | Genom Biotech Pvt. Ltd.India | Roymed PharmaceuticalImporter: Nelpa Lifesciences, Inc. | DRP-17484-01 | Jan 12, 2031 | |
FeburexFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Rexmed Pharmaceutical SalesImporter: Sanimed Pharmaceuticals Inc. | DRP-11620-5 | Apr 4, 2027 | |
Feburex 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 28's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: PH Phil Asia Medica Co. | DRP-15516-01 | Jul 30, 2029 | |
FeburicFebuxostat | 80 mg Film-Coated TabletClear PVC/Alu blister pack x 10's (box of 30) | Rx | Sanofi-Aventis De Mexico, S.A. De C.V.Mexico | Zuellig Pharma CorporationImporter: Astellas Pharma Philippines, Inc. | DR-XY45653 | Nov 28, 2026 | |
FeburichFebuxostat | 40mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | RV Lifesciences LimitedIndia | Medirich Pharma Distribution Corp.Importer: RV Group Phil. Branch | DRP-13982-03 | May 31, 2028 | |
FebusanFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-07 | Apr 4, 2027 | |
Febusap 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution And Consultancy Corp. | DRP-12601-13 | Sep 14, 2027 | |
Febusap 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-10 | Sep 14, 2027 | |
Febusap 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy | DRP-12600-11 | Sep 14, 2027 | |
FebuschwartzFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-10512-12 | Sep 22, 2037 | |
FebuschwartzFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 10's, 30's, 100's) | Rx | Innova Captab LimitedIndia | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-14532-07 | Oct 3, 2028 | |
Febuspar 40Febuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-18362 | Jun 18, 2031 | |
Febuspar 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-18390 | Jun 30, 2031 | |
FebustarFebuxostat | 40mg TabletAlu/Alu Blister Pack x 10 (Box of 30's) | Rx | Gracure Pharmaceuticals LtdIndia | Pharmastar Int'L Trading Corp. | DRP-18352 | Jun 18, 2032 | |
FebustinFebuxostat | 80 mg Film-Coated TabletAlu/PVDC Blister Pack x 14's (Box of 28's) | Rx | Standard Chem. & Pharm. Co., Ltd.Taiwan | Crisdy-Na Drug CorporationImporter: Standard Chem. & Pharm. Philippines, Inc. | DRP-11090-01 | Jun 1, 2031 | |
FebutechFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | One Technodrug Life Sciences Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-08 | Apr 4, 2027 | |
FebutonFebuxostat | 80 mg Film-Coated TabletAlu/PVDC Blister Pack x 14's (Box of 28's) | Rx | Standard Chem & Pharm Co., Ltd.Taiwan | Standard Chem & Pharm Philippines, Inc. | DRP-11090 | Jun 1, 2031 | |
Febutor - 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 14's and 28's) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48200 | Jul 19, 2027 | |
Febutor-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 14's and 28's) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48201 | Jul 20, 2027 | |
Febutor-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-12292-04 | Jul 12, 2027 | |
Febutor-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-12291-02 | Jul 11, 2027 | |
FebuwiseFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Medwise. Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-02 | Apr 4, 2027 | |
Febuxeb 40Febuxostat | 40 mg Film Coated TabletAlu/Alu Blister pack x 10's (Box of 10's) | Rx | Innova Captab Ltd. (Unit II)India | Ambica International Corporation.Importer: Ambica International Corporation | DRP-14532 | Oct 3, 2028 | |
Febuxeb 80Febuxostat | 80 mg Film Coated TabletAlu/Alu Blister pack x 10's (Box of 10's) | Rx | Innova Captab Ltd. (Unit II)India | Ambica International Corporation.Importer: Ambica International Corporation | DRP-14531 | Oct 3, 2028 | |
FebuxiproFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack X 10’s (Box of 30's) | Rx | Innova Captab Ltd. (Unit II)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-14531-02 | Oct 3, 2028 | |
Febuxoprim 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Cooper Pharma LimitedIndia | Titanium PharmaImporter: Ambica International Corporation | DRP-12292 | Jul 12, 2032 | |
Febuxoprim 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-12291 | Jul 11, 2032 | |
FebuxorinFebuxostat | 40 mg Film-Coated TabletAlu/Alu blister pack x 10 (Box of 10's and 30's) | Rx | Gracure Pharmaceutical Ltd.India | Despina Pharma Inc. | DRP-14198 | Jul 18, 2028 | |
FebuxospeedFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Speed Med Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-12292-01 | Jul 12, 2027 | |
FebuxospeedFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Speed Med Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-12291-01 | Jul 11, 2027 | |
FebuxtatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-11052-02 | Jan 19, 2032 | |
Febuzen 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | PH Phil Asia Medica Co. | DRP-15517 | Jul 30, 2029 | |
Febuzen 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 28's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | PH Phil Asia Medica Co. | DRP-15516 | Jul 30, 2029 | |
Febx 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-12292-06 | Jul 12, 2032 | |
Febx 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-12291-04 | Jul 11, 2027 | |
Febxollen-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sai Parenterals Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10752-02 | May 5, 2030 | |
Febxosaph-80Febuxostat | Film-Coated Tablet 80 mgAlu - Alu Blister Pack x 10’s (Box of 30’s) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc.Importer: Ollen Pharma Trading, Inc. | DRP-11814-01 | Mar 31, 2030 | |
FebxuscareFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-10512-09 | Aug 27, 2037 | |
FebxuscareFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-10511-07 | Aug 19, 2037 | |
FegoutFebuxostat | 40 mg Film-Coated TabletAlu/PVC Blister Pack x 10's | Rx | Koera United Pharm. Inc.Korea | United Douglas Pharm Philippines Inc. | DR-XY48727 | May 15, 2028 | |
FegoutFebuxostat | 80 mg Film-Coated TabletIn Alu/PVC Blister Pack x 10's | Rx | Korea United Pharm. Inc.Korea | — | DR-XY47866 | Mar 30, 2027 | |
Fevorica 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Ambica International Corporation | DRP-11052 | Jan 19, 2037 | |
Fevorica 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Ambica International Corporation | DRP-10613 | Nov 16, 2031 | |
FevxostFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10512-16 | Aug 27, 2037 | |
FevxostFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10511-06 | Aug 12, 2037 | |
Fexogout-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Excelcare, Inc.Importer: Ambica International Corporation | DRP-10512-05 | Sep 22, 2037 | |
FexoxanFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceuticals LimitedIndia | MC Graw Pharma Inc.Importer: Stangen Pharmaceuticals Philippines Inc. | DRP-10426-01 | Nov 4, 2031 | |
Fexustan 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-11620-04 | Apr 4, 2027 | |
Fixuric 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Ellebasy Medicale TradingImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-08 | Sep 14, 2027 | |
Fixuric 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Ellebasy Medicale TradingImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-06 | Sep 14, 2027 | |
FuricFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation | DRP-12292-10 | Jul 12, 2027 | |
FuricFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 100's) | Rx | Lupin LimitedIndia | Multicare Pharmaceuticals Philippines, Inc. | DRP-12324 | Oct 11, 2028 | |
FuricFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 100's) | Rx | Lupin LimitedIndia | Multicare Pharmaceuticals Philippines, Inc. | DRP-12357 | Oct 11, 2028 | |
FurinilFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-12292-03 | Jul 12, 2027 | |
FurinilFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Cooper Pharma LimitedIndia | Alkem Laboratories CorporationImporter: Ambica International Corporation | DRP-12291-03 | Jul 11, 2027 | |
GorticFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Medico Remedies LimitedIndia | MedEthix, Inc. | DRP-19108 | Oct 28, 2031 | |
Gortic-80Febuxostat | 80 mg Tablet | Rx | Medico Remedies LimitedIndia | Medethix, Inc. | DRP-17532 | Feb 6, 2031 | |
GourixFebuxostat | 80 mg Film-Coated TabletAlu-Alu blister pack x 10's(Box of 3 blister packs x 10 tablets) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.. | DRP-15840 | Sep 23, 2029 | |
GoutixostFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-10511-02 | Aug 6, 2037 | |
GoutrixFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Terramedic, Inc.Importer: AMB HK Enterprises Inc. | DRP-13086-05 | Nov 28, 2027 | |
GraxostatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Gracure Pharmaceutical Ltd.India | Healol Pharma Corporation | DRP-11564 | Mar 30, 2027 | |
Graxostat 80Febuxostat | 80 mg Film-Coated TabletsAlu/Alu blister pack x 10’s (Box of 30’s) | Rx | RV Lifesciences LimitedIndia | Healol Pharma CorporationImporter: RV Group Phil. Branch | DRP-13981-03 | May 31, 2028 | |
Jiaastat-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Globela Pharma Private LimitedIndia | Jiaa PharmaImporter: AMB HK Enterprises Inc. | DRP-13086-03 | Nov 28, 2027 | |
Jiaastat-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Globela Pharma Private LimitedIndia | Jiaa PharmaImporter: AMB HK Enterprises Inc. | DRP-13085-02 | Nov 28, 2027 | |
Laboxtat 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Labmate Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-01 | Sep 14, 2027 | |
Laboxtat 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Labmate Pharma Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-02 | Sep 14, 2027 | |
Lesurix 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10512-03 | Aug 27, 2037 | |
Lesurix 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10511-11 | Aug 17, 2037 | |
Maxibustat 40Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-02 | Sep 14, 2027 | |
Maxibustat 80Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Importer: Afree Pharmaceutical Distribution Corp. | DRP-12600-01 | Sep 14, 2027 | |
MeduroxicFebuxostat | 40mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's). | Rx | Mankind Pharma Limited (Unit II)India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-13408 | Feb 14, 2028 | |
MeduroxicFebuxostat | 80mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's). | Rx | Mankind Pharma Limited (Unit II)India | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-13308 | Jan 24, 2028 | |
NeogoutFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack X 10’s (Box of 30's) | Rx | Innova Captab Ltd. (Unit II)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-14532-01 | Oct 3, 2028 | |
NoneFebuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bio-Labs (Pvt) Ltd.Pakistan | Watsons Personal Care Stores (Philippines), Inc.Importer: Nueva Sunshine Phils., Inc. | DRP-14913-01 | Feb 8, 2029 | |
NoneFebuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Labmate Pharma, Inc.Importer: AMB HK Enterprises, Inc. | DRP-17016-01 | Sep 5, 2030 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab LimitedIndia | Actimed, Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10408-02 | Aug 1, 2029 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-10512-06 | Sep 1, 2037 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | South Star DrugImporter: Ambica International Corporation | DRP-10512-15 | Sep 11, 2037 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s and 100's) | Rx | Cooper Pharma LimitedIndia | South Star DrugImporter: Ambica International Corporation | DRP-12292-09 | Jul 12, 2027 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Excelcare, Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-10 | Sep 14, 2027 | |
NoneFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Reta DrugImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-14 | Sep 14, 2027 | |
NoneFebuxostat | 80 mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Exemed PharmaceuticalsIndia | Labmate Pharma, Inc.Importer: Amb HK Enterprises, Inc. | DRP-17015-01 | Sep 5, 2030 | |
NoneFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10409-02 | Aug 1, 2029 | |
NoneFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Philippine Home PharmaceuticalsImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-05 | Sep 17, 2027 | |
NoneFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Ellebasy Medicale TradingImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-07 | Sep 14, 2027 | |
NoneFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Ellebasy Medicale TradingImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-08 | Sep 14, 2027 | |
Noric 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Justright Healthcare Inc.Importer: Ambica International Corporation | DRP-10512-14 | Aug 27, 2037 | |
PremigoutFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Innova Captab LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation | DRP-14531-05 | Oct 3, 2028 | |
ProvixostatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Providencia Medica Inc.Importer: Ambica International Corporation | DRP-12292-07 | Jul 12, 2027 | |
Q-TemFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | All-Bio Pharma, Inc.Importer: Ambica International Corporation | DRP-10512-07 | Oct 10, 2037 | |
QricFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-13086-01 | Nov 28, 2027 | |
Qric 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-13085-1 | Nov 28, 2027 | |
QuricFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Philippine Home PharmaceuticalsImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-09 | Sep 14, 2027 | |
RenoxalFebuxostat | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Importer: AMB HK Enterprises Inc. | DRP-14003 | Jun 2, 2028 | |
RetabustatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | Rx | Innova Captab LimitedIndia | Reta DrugImporter: Ambica International Corporation | DRP-14532-05 | Oct 3, 2028 | |
RetaxostatFebuxostat | 80 mg Film-Coated TabletAlu-Alu Blister pack of 10's (Box of 10's and Box of 100's) | Rx | Acme Formulation Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-11461-02 | Mar 15, 2027 | |
RifexostatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Cooper Pharma LimitedIndia | Rifemedica CorporationImporter: Ambica International Corporation | DRP-12292-02 | Jul 12, 2027 | |
Rulestat-40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Innova Captab LimitedIndia | Rule Med Pharma Corp.Importer: Ambica International Corporation | DRP-14532-08 | Oct 3, 2028 | |
Saphuric-GE40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17484 | Jan 12, 2031 | |
Saphuric-GE80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17483 | Jan 12, 2031 | |
Saphxostat-80Febuxostat | 80 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Sai Parenterals Ltd.India | Ollen Pharma Trading, Inc. | DRP-11814 | Mar 31, 2030 | |
ShinstatFebuxostat | 40 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Genuone Sciences Inc.Korea | Phil Shinpoong Pharma, Inc. | DRP-16799 | Aug 1, 2030 | |
ShinstatFebuxostat | 80 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Genuone Sciences Inc.Korea | Phil Shinpoong Pharma, Inc. | DRP-16798 | Aug 1, 2030 | |
Sitibast-40Febuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | BIO-LABS (PVT) LTD.Pakistan | One Dexcel Pharma Inc.Importer: Nueva Sunshine Phils., Inc. | DRP-14913 | Feb 8, 2029 | |
Sitibast-80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bio-Labs (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc.Importer: Nueva Sunshine Phils., Inc. | DRP-14914 | Feb 8, 2029 | |
Stabufost 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Ambica International Corporation | DRP-11053 | Jan 19, 2032 | |
Stabufost 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Acme Formulation Pvt. Ltd.India | Ambica International Corporation | DRP-10614 | Nov 16, 2031 | |
StaturicFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Msn Laboratories Private Limited (Formulation Division)India | MSN Labs Philippines Inc.Importer: Healol Pharma Corporation | DRP-8533-01 | Jul 20, 2027 | |
SurixtatFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | Sierra Pharmaceutical CorporationImporter: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-11 | Sep 14, 2027 | |
UnbrandedFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Rose Pharmacy, IncorporatedImporter: Ambica International Corporation | DRP-10512-02 | Sep 19, 2037 | |
UnbrandedFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-10511-03 | Aug 19, 2037 | |
Uri-SFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-10512-10 | Aug 26, 2037 | |
UricaFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30's) | Rx | Advanced Chemical Industries (ACI) Ltd.Bangladesh | The Cathay Drug Co., Inc. | DR-XY44896 | Nov 24, 2030 | |
UricaFebuxostat | 40 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | The Cathay Drug Co. Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12601-04 | Sep 14, 2027 | |
UricaFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30's) | Rx | Advanced Chemical Industries (ACI) Ltd.Bangladesh | The Cathay Drug Co., Inc. | DR-XY45021 | Jan 29, 2031 | |
UricaFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (Box of 30's) | Rx | Sunrise International Labs LimitedIndia | The Cathay Drug Co., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp. | DRP-12600-04 | Sep 14, 2027 | |
UricaidFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | GX International, Inc.Importer: Ambica International Corporation | DRP-10512-13 | Sep 11, 2037 | |
UricalevFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | MAGBRO HEALTHCARE PVT. LTD.India | Pharmakon Biotec Inc. | DRP-16466 | Mar 20, 2030 | |
UricgoFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | IJA Pharma DistributorImporter: AMB HK Enterprises Inc. | DRP-13086-04 | Nov 28, 2027 | |
UricureFebuxostat | 80 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17015 | Sep 5, 2030 | |
UrigenFebuxostat | 80 mg Film-Coated TabletAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-18317 | Jun 10, 2032 | |
UrinormFebuxostat | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma LimitedIndia | UNILAB, Inc.Trader: Anvaxx Laboratories | DRP-10931 | Jan 18, 2027 | |
UrinormFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ajanta Pharma LimitedIndia | UNILAB, Inc. | DRP-10057 | May 2, 2031 | |
UrinormFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30') | Rx | Ajanta Pharma LimitedIndia | UNILAB, Inc. | DRP-10058 | May 2, 2031 | |
UristatFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Oxpharm Inc.Importer: AMB HK Enterprises Inc. | DRP-13086-02 | Nov 28, 2027 | |
UrixFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab LimitedIndia | Jackpharma Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10408-01 | Aug 1, 2029 | |
UrixFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Innova Captab Ltd.India | Jackpharma Inc.Importer: Medethix, Inc.Trader: Aztec Pharma Pvt. Ltd. | DRP-10409-01 | Aug 1, 2029 | |
UrixaFebuxostat | 40 mg Film-Coated TabletAlu/Alu blister pack x 10 (Box of 10’s, 30's, 60's, & 100's) | Rx | Gracure Pharmaceutical Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14198-01 | Jul 18, 2028 | |
Urixokind-40Febuxostat | 40mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-13409 | Mar 2, 2028 | |
Urixokind-80Febuxostat | 80mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-13208 | Dec 29, 2027 | |
UrostarFebuxostat | 80mg Film-Coated TabletAlu/Alu Blister pack of 10's (Box of 10's and 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DR-XY47066 | Dec 29, 2027 | |
UstavixFebuxostat | 40 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 10’s, 30’s, 60’s, 100's) | Rx | Gracure Pharmaceutical Ltd.India | D&G PharmaImporter: Despina Pharma Inc. | DRP-14198-02 | Jul 18, 2028 | |
UxentaFebuxostat | 40 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17017 | Sep 5, 2030 | |
UxentaFebuxostat | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private Limited.India | Oxpharm Inc.Importer: AMB HK Enterprises Inc. | DRP-14073 | Jun 13, 2028 | |
UxentaFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17018 | Sep 5, 2030 | |
Vexbos 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | ACME Formulation Pvt. Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY49276 | Nov 14, 2029 | |
Vexbos 80Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | ACME Formulation Pvt. Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY48425 | Oct 26, 2027 | |
XorinFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Innovative HealthcareIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-17351 | Nov 19, 2030 | |
XorinFebuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Innovative HealthcareIndia | Biophil Medical Equipment and Supplies Trading | DRP-17350 | Nov 19, 2030 | |
XozidFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Trumed PharmaceuticalsImporter: AMB HK Enterprises, Inc. | DRP-14003-01 | Jun 2, 2028 | |
Xuric 40Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | Rx | Globela Pharma Private Limited.India | AMB HK Enterprises Inc. | DRP-15535 | Jul 31, 2029 | |
Xuric 40Febuxostat | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Importer: AMB HK Enterprises Inc. | DRP-13086 | Nov 28, 2027 | |
Zure-UricFebuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-10512-11 | Sep 17, 2037 | |
(no brand name)Febuxostat | 40 mg Film-Coated TabletAlu/Alu Strip Pack x 10's (Box of 30's) | Rx | Ajanta Pharma LimitedIndia | RiteMED Phls., Inc. | DR-XY48099 | Jun 9, 2027 | |
(no brand name)Febuxostat | 40 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | ACI HealthCare LimitedBangladesh | Firmlink Pharma Phils. Co. | DR-XY49708 | May 13, 2031 | |
(no brand name)Febuxostat | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Nelpa Lifesciences, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10752-01 | Nov 16, 2026Past listed date | |
(no brand name)Febuxostat | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | — | DRP-13881 | May 11, 2028 | |
(no brand name)Febuxostat | 80 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 30's) | Rx | ACI HealthCare LimitedBangladesh | Firmlink Pharma Phils. Co. | DR-XY49707 | May 7, 2031 | |
(no brand name)Febuxostat | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Medico Remedies LimitedIndia | Medethix, Inc. | DRP-13951 | May 30, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 40 mg tablets, light green to green, round, debossed with "TAP" and "40" 80 mg tablets, light green to green, teardrop shaped, debossed with "TAP" and "80" Tablet: 40 mg, 80 mg. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Gout Flares: An increase in gout flares is frequently observed after initiation of ULORIC. If a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug or colchicine) upon initiation of treatment may be beneficial for up to six months. (2.4, 5.2)
- Hepatic Effects: Cases of hepatic failure, some fatal, have been reported. If liver injury is detected, promptly interrupt ULORIC and treat cause, if possible, to resolution or stabilization. Permanently discontinue ULORIC if liver injury is confirmed, and no alternate etiology can be found. (5.3)
- Serious Skin Reactions: Serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms and toxic epidermal necrolysis have been reported in patients taking ULORIC. Discontinue ULORIC if serious skin reactions are suspected. (5.4)
5.1 Cardiovascular Death
5.1 Cardiovascular Death In a cardiovascular (CV) outcome study, gout patients with established CV disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol. Sudden cardiac death was the most common cause of adjudicated CV deaths, 2.7% in the ULORIC group (83 of 3,098) as compared to 1.8% in the allopurinol group (56 of 3,092).
ULORIC was similar to allopurinol for nonfatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization [see Clinical Studies (14.2)]. Because of the increased risk of CV death, ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage(1)].
Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. Monitor patients for the development of CV events. Inform patients about the symptoms of serious CV events and the steps to take if they occur.
5.2 Gout Flares
5.2 Gout Flares After initiation of ULORIC, an increase in gout flares is frequently observed. This increase is due to reduction in serum uric acid levels, resulting in mobilization of urate from tissue deposits. In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4)].
5.3 Hepatic Effects
5.3 Hepatic Effects Cases of fatal and nonfatal hepatic failure in patients taking ULORIC have been reported. During randomized controlled studies, transaminase elevations greater than three times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively).
No dose-effect relationship for these transaminase elevations was noted [see Clinical Pharmacology (12.3)]. Obtain a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) as a baseline before initiating ULORIC. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.
In this clinical context, if the patient presents abnormal liver tests (ALT or AST greater than three times the upper limit of the reference range), interrupt ULORIC treatment while investigating the probable cause. Permanently discontinue ULORIC if liver injury is confirmed, and no alternate etiology can be found. Permanently discontinue ULORIC in patients who have serum ALT or AST greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies because they are at risk for severe drug-induced liver injury.
For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with ULORIC can be used with close monitoring.
5.4 Serious Skin Reactions
5.4 Serious Skin Reactions Serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) have been reported postmarketing in patients taking ULORIC. Discontinue ULORIC if serious skin reactions are suspected [see Patient Counseling Information (17)].
Many of these patients had reported previous similar skin reactions to allopurinol. ULORIC should be used with close monitoring in these patients.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Azathioprine, mercaptopurine | Avoid | Higher 6-mercaptopurine exposure; severe toxicity. | Contraindicated. |
| Theophylline | Adjust or monitor | Altered theophylline (xanthine oxidase substrate) metabolism. | Use with caution. |
| Cytotoxic chemotherapy | Minor | Not studied; no safety data. | No data; avoid unless necessary. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedConcomitant administration of ULORIC with XO substrate drugs, azathioprine or mercaptopurine could increase plasma concentrations of these drugs resulting in severe toxicity. (7)
7.1 Xanthine Oxidase Substrate Drugs
7.1 Xanthine Oxidase Substrate Drugs ULORIC is an XO inhibitor. Based on a drug interaction study in healthy patients, febuxostat altered the metabolism of theophylline (a substrate of XO) in humans [see Clinical Pharmacology (12.3)]. Therefore, use with caution when coadministering ULORIC with theophylline. A drug interaction study of ULORIC and azathioprine, also metabolized by XO, showed an increase in exposure of 6-mercaptopurine which may lead to toxicity [see Clinical Pharmacology (12.3)].
Drug interaction studies of ULORIC with other drugs that are metabolized by XO (e.g., mercaptopurine) have not been conducted. ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Contraindications (4)].
7.2 Cytotoxic Chemotherapy Drugs
7.2 Cytotoxic Chemotherapy Drugs Drug interaction studies of ULORIC with cytotoxic chemotherapy have not been conducted. No data are available regarding the safety of ULORIC during cytotoxic chemotherapy.
7.3 In Vivo Drug Interaction Studies
7.3 In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3)]. Therefore, ULORIC may be used concomitantly with these medications.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Febuxostat is extensively metabolized by both conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 and 2C9 and non-P450 enzymes.
P450 Substrate Drugs In vitro studies have shown that febuxostat does not inhibit P450 enzymes CYP1A2, 2C9, 2C19, 2D6, or 3A4 and it also does not induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant concentrations.
Desipramine Coadministration of drugs that are CYP2D6 substrates (such as desipramine) with ULORIC are not expected to require dose adjustment.
Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro and in vivo .
Adverse reactions
Common
- Liver function abnormalities, nausea, arthralgia, rash (≥1%)
Serious
- Cardiovascular death in gout patients with established cardiovascular disease (boxed warning; higher than allopurinol in CARES)
- Fatal and nonfatal hepatic failure
- Serious skin and hypersensitivity reactions
- Gout flares after starting
- The following serious adverse reactions are described elsewhere in the prescribing information: Cardiovascular Death [see Warnings and Precautions (5.1)] Hepatic Effects [see Warnings and Precautions (5.3)] Serious Skin Reactions [see Warnings and Precautions (5.4)] Adverse reactions in ≥ 1% of patients treated with ULORIC are liver function abnormalities, nausea, arthralgia, and rash. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In Phase 2 and 3 clinical studies, a total of 2757 patients with hyperuricemia and gout were treated with ULORIC 40 mg or 80 mg daily.
For ULORIC 40 mg, 559 patients were treated for ≥6 months. For ULORIC 80 mg, 1377 patients were treated for ≥6 months, 674 patients were treated for ≥1 year and 515 patients were treated for ≥2 years. In the CARES study, a total of 3098 patients were treated with ULORIC 40 mg or 80 mg daily; of these, 2155 patients were treated for ≥1 year and 1539 were treated for ≥2 years [see Clinical Studies (14.2)].
Most Common Adverse Reactions In three randomized, controlled clinical studies (Studies 1, 2 and 3), which were 6 to 12 months in duration, the following adverse reactions were reported by the treating physician as related to study drug. Table 1 summarizes adverse reactions reported at a rate of at least 1% in ULORIC treatment groups and at least 0.5% greater than placebo.
Table 1: Adverse Reactions Occurring in ≥1% of Patients Treated with ULORIC and at Least 0.5% Greater than in Patients Receiving Placebo in Controlled Studies Placebo ULORIC allopurinol Of the patients who received allopurinol, 10 received 100 mg, 145 received 200 mg, and 1122 received 300 mg, based on level of renal impairment. Adverse Reactions (N=134) 40 mg daily (N=757) 80 mg daily (N=1279) (N=1277) Liver Function Abnormalities 0.7% 6.6% 4.6% 4.2% Nausea 0.7% 1.1% 1.3% 0.8% Arthralgia 0% 1.1% 0.7% 0.7% Rash 0.7% 0.5% 1.6% 1.6% The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of patients treated with allopurinol.
In addition to the adverse reactions presented in Table 1, dizziness was reported in more than 1% of patients treated with ULORIC although not at a rate more than 0.5% greater than placebo. In the CARES study, liver function abnormalities and diarrhea were reported in more than 1% of patients treated with ULORIC, although not at a rate more than 0.5% greater than allopurinol.
Less Common Adverse Reactions In clinical studies the following adverse reactions occurred in less than 1% of patients and in more than one subject treated with doses ranging from 40 mg to 240 mg of ULORIC. This list also includes adverse reactions (less than 1% of patients) associated with organ systems from Warnings and Precautions.
Blood and Lymphatic System Disorders: anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia. Cardiac Disorders: angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia. Ear and Labyrinth Disorders: deafness, tinnitus, vertigo.
Eye Disorders: vision blurred. Gastrointestinal Disorders: abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, hematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.
General Disorders and Administration Site Conditions: asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst. Hepatobiliary Disorders: cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly. Immune System Disorder: hypersensitivity.
Infections and Infestations: herpes zoster. Procedural Complications: contusion. Metabolism and Nutrition Disorders: anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased. Musculoskeletal and Connective Tissue Disorders: arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.
Nervous System Disorders: altered taste, balance disorder, cerebrovascular accident, Guillain-Barré syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor. Psychiatric Disorders: agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.
Renal and Urinary Disorders: hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence. Reproductive System and Breast Changes: breast pain, erectile dysfunction, gynecomastia. Respiratory, Thoracic and Mediastinal Disorders: bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.
Skin and Subcutaneous Tissue Disorders: alopecia, angio edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis, peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria. Vascular Disorders: flushing, hot flush, hypertension, hypotension.
Laboratory Parameters: activated partial thromboplastin time prolonged, creatine increased, bicarbonate decreased, sodium increased, EEG abnormal, glucose increased, cholesterol increased, triglycerides increased, amylase increased, potassium increased, TSH increased, platelet count decreased, hematocrit decreased, hemoglobin decreased, MCV increased, RBC decreased, creatinine increased, blood urea increased, BUN/creatinine ratio increased, creatine phosphokinase (CPK) increased, alkaline phosphatase increased, LDH increased, PSA increased, urine output increased/decreased, lymphocyte count decreased, neutrophil count decreased, WBC increased/decreased, coagulation test abnormal, low density lipoprotein (LDL) increased, prothrombin time prolonged, urinary casts, urine positive for white blood cells and protein.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of ULORIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: agranulocytosis, eosinophilia.
Hepatobiliary Disorders: hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder. Immune System Disorders: anaphylaxis, anaphylactic reaction. Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis. Psychiatric Disorders: psychotic behavior including aggressive thoughts.
Renal and Urinary Disorders: tubulointerstitial nephritis. Skin and Subcutaneous Tissue Disorders: generalized rash, Stevens-Johnson Syndrome, hypersensitivity skin reactions, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, toxic epidermal necrolysis.
Adverse reaction frequency tables (US label) US FDA label
| Placebo | ULORIC | allopurinolOf the patients who received allopurinol, 10 received 100 mg, 145 received 200 mg, and 1122 received 300 mg, based on level of renal impairment. | ||
|---|---|---|---|---|
| Adverse Reactions | (N=134) | 40 mg daily (N=757) | 80 mg daily (N=1279) | (N=1277) |
| Liver Function Abnormalities | 0.7% | 6.6% | 4.6% | 4.2% |
| Nausea | 0.7% | 1.1% | 1.3% | 0.8% |
| Arthralgia | 0% | 1.1% | 0.7% | 0.7% |
| Rash | 0.7% | 0.5% | 1.6% | 1.6% |
Monitoring parameters
- Serum urate; liver tests per label. The label carries a boxed warning on cardiovascular death. Kidney
- Serum urate (target below 6 mg/dL) from 2 weeks
- Liver tests before starting and if symptoms of liver injury
- Signs of myocardial infarction or stroke
- Flare prophylaxis with an NSAID or colchicine when starting
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Limited available data with ULORIC use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. No adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (MRHD).
No adverse developmental effects were observed in a pre- and postnatal development study with administration of febuxostat to pregnant rats from organogenesis through lactation at an exposure approximately 11 times the MRHD (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation Days 7 – 17, febuxostat was not teratogenic and did not affect fetal development or survival at exposures up to approximately 40 times the MRHD (on an AUC basis at maternal oral doses up to 48 mg/kg/day).
In an embryo-fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation Days 6 – 18, febuxostat was not teratogenic and did not affect fetal development at exposures up to approximately 51 times the MRHD (on an AUC basis at maternal oral doses up to 48 mg/kg/day). In a pre- and postnatal development study in pregnant female rats dosed orally from gestation Day 7 through lactation Day 20, febuxostat had no effects on delivery or growth and development of offspring at a dose approximately 11 times the MRHD (on an AUC basis at a maternal oral dose of 12 mg/kg/day).
However, increased neonatal mortality and a reduction in neonatal body weight gain were observed in the presence of maternal toxicity at a dose approximately 40 times the MRHD (on an AUC basis at a maternal oral dose of 48 mg/kg/day). Febuxostat crossed the placental barrier following oral administration to pregnant rats and was detected in fetal tissues.
Mechanism of action
12.1 Mechanism of Action ULORIC, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. ULORIC is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Effect on Uric Acid and Xanthine Concentrations In healthy patients, ULORIC resulted in a dose dependent decrease in 24-hour mean serum uric acid concentrations and an increase in 24-hour mean serum xanthine concentrations. In addition, there was a decrease in the total daily urinary uric acid excretion.
Also, there was an increase in total daily urinary xanthine excretion. Percent reduction in 24-hour mean serum uric acid concentrations was between 40% and 55% at the exposure levels of 40 mg and 80 mg daily doses. Effect on Cardiac Repolarization The effect of ULORIC on cardiac repolarization as assessed by the QTc interval was evaluated in normal healthy patients and in patients with gout.
ULORIC in doses up to 300 mg daily (3.75 times the maximum recommended daily dosage), at steady-state, did not demonstrate an effect on the QTc interval.
Pharmacokinetics
Key PK parameters
| Bioavailability | At least 49% absorbed (absolute bioavailability not studied) |
|---|---|
| Half-life | About 5 to 8 hours |
| Half-life in kidney failure (ESKD) kidney | Not studied in ESKD; AUC up to 1.8-fold and longer half-life at CrCl 10 to 29 mL/min (label) |
| Volume of distribution | About 50 L (Vss/F) |
| Protein binding | About 99.2% (albumin) |
| Metabolism (CYP, transporters) | UGT1A1, 1A3, 1A9, 2B7 conjugation; CYP1A2, 2C8, 2C9 oxidation |
| Active metabolites | Four hydroxy metabolites (much lower plasma levels than parent) |
| Renal excretion kidney | About 49% in urine (3% unchanged); about 45% in feces |
| Dialyzability kidney | Unknown: not studied (label). |
Febuxostat has an apparent mean terminal elimination half-life (t 1/2 ) of approximately 5 to 8 hours.
In addition to the urinary excretion, approximately 45% of the dose was recovered in the feces as the unchanged febuxostat (12%), the acyl glucuronide of the drug (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).
The apparent mean terminal elimination half-life (t 1/2 ) of febuxostat was approximately 5 to 8 hours.
AUC and half-life of febuxostat increased in patients with renal impairment in comparison to patients with normal renal function, but values were similar among three renal impairment groups.
A drug-drug interaction study evaluating the effect of ULORIC upon the pharmacokinetics of theophylline (an XO substrate) in healthy patients showed that coadministration of febuxostat with theophylline resulted in an approximately 400-fold increase in the amount of 1-methylxanthine, one of the major metabolites of theophylline, excreted in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics In healthy patients, maximum plasma concentrations (C max) and AUC of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg (0.25 times the lowest recommended dosage) to 120 mg (1.5 times the maximum recommended dosage). There is no accumulation when therapeutic doses are administered every 24 hours.
Febuxostat has an apparent mean terminal elimination half-life (t 1/2) of approximately 5 to 8 hours. Febuxostat pharmacokinetic parameters for patients with hyperuricemia and gout estimated by population pharmacokinetic analyses were similar to those estimated in healthy patients. Absorption The absorption of radiolabeled febuxostat following oral dose administration was estimated to be at least 49% (based on total radioactivity recovered in urine).
Maximum plasma concentrations of febuxostat occurred between 1 and 1.5 hours postdose. After multiple oral 40 mg and 80 mg once daily doses, C max is approximately 1.6 ± 0.6 mcg/mL (N=30), and 2.6 ± 1.7 mcg/mL (N=227), respectively. Absolute bioavailability of the febuxostat tablet has not been studied. Following multiple 80 mg once daily doses with a high fat meal, there was a 49% decrease in C max and an 18% decrease in AUC, respectively.
However, no clinically significant change in the percent decrease in serum uric acid concentration was observed (58% fed vs 51% fasting). Thus, ULORIC may be taken without regard to food. Concomitant ingestion of an antacid containing magnesium hydroxide and aluminum hydroxide with an 80 mg single dose of ULORIC has been shown to delay absorption of febuxostat (approximately one hour) and to cause a 31% decrease in C max and a 15% decrease in AUC ∞.
As AUC rather than C max was related to drug effect, change observed in AUC was not considered clinically significant. Therefore, ULORIC may be taken without regard to antacid use. Distribution The mean apparent steady state volume of distribution (V ss /F) of febuxostat was approximately 50 L (CV ~40%). The plasma protein binding of febuxostat is approximately 99.2% (primarily to albumin), and is constant over the concentration range achieved with 40 mg and 80 mg doses.
Metabolism Febuxostat is extensively metabolized by both conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 and 2C9 and non-P450 enzymes. The relative contribution of each enzyme isoform in the metabolism of febuxostat is not clear.
The oxidation of the isobutyl side chain leads to the formation of four pharmacologically active hydroxy metabolites, all of which occur in plasma of humans at a much lower extent than febuxostat. In urine and feces, acyl glucuronide metabolites of febuxostat (~35% of the dose), and oxidative metabolites, 67M-1 (~10% of the dose), 67M-2 (~11% of the dose), and 67M-4, a secondary metabolite from 67M-1 (~14% of the dose), appeared to be the major metabolites of febuxostat in vivo.
Elimination Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14 C-labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the drug (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%).
In addition to the urinary excretion, approximately 45% of the dose was recovered in the feces as the unchanged febuxostat (12%), the acyl glucuronide of the drug (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%). The apparent mean terminal elimination half-life (t 1/2) of febuxostat was approximately 5 to 8 hours.
Specific Populations Geriatric Patients The C max and AUC of febuxostat and its metabolites following multiple oral doses of ULORIC in geriatric patients (≥65 years) were similar to those in younger patients (18 to 40 years). In addition, the percent decrease in serum uric acid concentration was similar between elderly and younger patients.
No dose adjustment is necessary in geriatric patients [see Use in Specific Populations (8.5)]. Patients with Renal Impairment In a dedicated phase I pharmacokinetics study, following multiple 80 mg doses of ULORIC in healthy patients with mild (Cl cr 50 to 80 mL/min), moderate (Cl cr 30 to 49 mL/min) or severe renal impairment (Cl cr 10 to 29 mL/min), the C max of febuxostat did not change relative to patients with normal renal function (Cl cr greater than 80 mL/min).
AUC and half-life of febuxostat increased in patients with renal impairment in comparison to patients with normal renal function, but values were similar among three renal impairment groups. Mean febuxostat AUC values were up to 1.8 times higher in patients with renal impairment compared to those with normal renal function.
Mean C max and AUC values for three active metabolites increased up to two and four-fold, respectively. However, the percent decrease in serum uric acid concentration for patients with renal impairment was comparable to those with normal renal function (58% in normal renal function group and 55% in the severe renal function group).
Based on population pharmacokinetic analysis, following multiple 40 mg or 80 mg doses of ULORIC, the mean oral clearance (CL/F) values of febuxostat in patients with gout and mild (n=334), moderate (n=232) or severe (n=34) renal impairment were decreased by 14%, 34%, and 48%, respectively, compared to patients with normal (n=89) renal function. The corresponding median AUC values of febuxostat at steady-state in patients with renal impairment were increased by 18%, 49%, and 96% after 40 mg dose, and 7%, 45% and 98% after 80 mg dose, respectively, compared to patients with normal renal function.
ULORIC has not been studied in end stage renal impairment patients who are on dialysis. Patients with Hepatic Impairment Following multiple 80 mg doses of ULORIC in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, an average of 20% to 30% increase was observed for both C max and AUC 24 (total and unbound) in hepatic impairment groups compared to patients with normal hepatic function.
In addition, the percent decrease in serum uric acid concentration was comparable between different hepatic groups (62% in healthy group, 49% in mild hepatic impairment group, and 48% in moderate hepatic impairment group). No dose adjustment is necessary in patients with mild or moderate hepatic impairment. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C); caution should be exercised in those patients [see Use in Specific Populations (8.7)].
Male and Female Patients Following multiple oral doses of ULORIC, the C max and AUC 24 of febuxostat were 30% and 14% higher in females than in males, respectively. However, weight-corrected C max and AUC were similar between the genders. In addition, the percent decrease in serum uric acid concentrations was similar between genders.
No dose adjustment is necessary based on gender. Racial Groups No specific pharmacokinetic study was conducted to investigate the effects of race. Drug Interaction Studies Effect of ULORIC on Other Drugs Xanthine Oxidase Substrate Drugs-Azathioprine, Mercaptopurine, and Theophylline Febuxostat is an XO inhibitor. A drug-drug interaction study evaluating the effect of ULORIC upon the pharmacokinetics of theophylline (an XO substrate) in healthy patients showed that coadministration of febuxostat with theophylline resulted in an approximately 400-fold increase in the amount of 1-methylxanthine, one of the major metabolites of theophylline, excreted in the urine.
Since the long-term safety of exposure to 1-methylxanthine in humans is unknown, use with caution when coadministering febuxostat with theophylline. A drug interaction study of ULORIC and azathioprine has been conducted [see Drug Interactions (7)]. Inhibition of XO by ULORIC caused increased plasma concentrations of 6-mercaptopurine, a metabolite of azathioprine, which may lead to toxicity.
Drug interaction studies of ULORIC with other drugs that are metabolized by XO (e.g., mercaptopurine) have not been conducted. ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Contraindications (4) and Drug Interactions (7)]. Azathioprine and mercaptopurine undergo metabolism via three major metabolic pathways, one of which is mediated by XO.
Concomitant administration of allopurinol [a xanthine oxidase inhibitor] with azathioprine or mercaptopurine has been reported to substantially increase plasma concentrations of these drugs. Because ULORIC is a xanthine oxidase inhibitor, it could inhibit the XO-mediated metabolism of mercaptopurine leading to increased plasma concentrations of mercaptopurine that could result in severe toxicity.
P450 Substrate Drugs In vitro studies have shown that febuxostat does not inhibit P450 enzymes CYP1A2, 2C9, 2C19, 2D6, or 3A4 and it also does not induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant concentrations. As such, pharmacokinetic interactions between ULORIC and drugs metabolized by these CYP enzymes are unlikely.
Effect of Other Drugs on ULORIC Febuxostat is metabolized by conjugation and oxidation via multiple metabolizing enzymes. The relative contribution of each enzyme isoform is not clear. Drug interactions between ULORIC and a drug that inhibits or induces one particular enzyme isoform is in general not expected. In Vivo Drug Interaction Studies Azathioprine Concomitant use of ULORIC and azathioprine is contraindicated.
Coadministration with febuxostat (40 mg or 120 mg QD) reduced the apparent clearance of mercaptopurine, a XO substrate, by 83.2% to 83.8% following a single oral dose of azathioprine, a prodrug of 6-mercaptopurine. No significant differences were observed in the extent of inhibition of 6-mercaptopurine metabolism by febuxostat 40 mg and 120 mg.
Theophylline No dose adjustment is necessary for theophylline when coadministered with ULORIC. Administration of ULORIC (80 mg once daily) with theophylline resulted in an increase of 6% in C max and 6.5% in AUC of theophylline. These changes were not considered statistically significant. However, the study also showed an approximately 400-fold increase in the amount of 1-methylxanthine (one of the major theophylline metabolites) excreted in urine as a result of XO inhibition by ULORIC.
The safety of long-term exposure to 1-methylxanthine has not been evaluated. This should be taken into consideration when deciding to coadminister ULORIC and theophylline. Colchicine No dose adjustment is necessary for either ULORIC or colchicine when the two drugs are coadministered. Administration of ULORIC (40 mg once daily) with colchicine (0.6 mg twice daily) resulted in an increase of 12% in C max and 7% in AUC 24 of febuxostat.
In addition, administration of colchicine (0.6 mg twice daily) with ULORIC (120 mg daily) resulted in a less than 11% change in C max or AUC of colchicine for both AM and PM doses. These changes were not considered clinically significant. Naproxen No dose adjustment is necessary for ULORIC or naproxen when the two drugs are coadministered.
Administration of ULORIC (80 mg once daily) with naproxen (500 mg twice daily) resulted in a 28% increase in C max and a 40% increase in AUC of febuxostat. The increases were not considered clinically significant. In addition, there were no significant changes in the C max or AUC of naproxen (less than 2%). Indomethacin No dose adjustment is necessary for either ULORIC or indomethacin when these two drugs are coadministered.
Administration of ULORIC (80 mg once daily) with indomethacin (50 mg twice daily) did not result in any significant changes in C max or AUC of febuxostat or indomethacin (less than 7%). Hydrochlorothiazide No dose adjustment is necessary for ULORIC when coadministered with hydrochlorothiazide. Administration of ULORIC (80 mg) with hydrochlorothiazide (50 mg) did not result in any clinically significant changes in C max or AUC of febuxostat (less than 4%), and serum uric acid concentrations were not substantially affected.
Warfarin No dose adjustment is necessary for warfarin when coadministered with ULORIC. Administration of ULORIC (80 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy patients. INR and Factor VII activity were also not affected by the coadministration of ULORIC. Desipramine Coadministration of drugs that are CYP2D6 substrates (such as desipramine) with ULORIC are not expected to require dose adjustment.
Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro and in vivo. Administration of ULORIC (120 mg once daily) with desipramine (25 mg) resulted in an increase in C max (16%) and AUC (22%) of desipramine, which was associated with a 17% decrease in the 2-hydroxydesipramine to desipramine metabolic ratio (based on AUC).
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ULORIC · Takeda Pharmaceuticals America, Inc. [US FDA-approved label, version 17, December 24, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Takeda Pharmaceuticals America, Inc.. (2025). ULORIC (febuxostat) [Prescribing information; US FDA-approved label, NDA021856, set ID 54de10ef-fe5f-4930-b91d-6bbb04c664bd, version effective December 24, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .

